Media stories about Tigenix (NASDAQ:TIG) have been trending positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tigenix earned a news sentiment score of 0.35 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0802580998027 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

A number of brokerages recently commented on TIG. Canaccord Genuity set a $30.00 price target on Tigenix and gave the stock a “buy” rating in a report on Tuesday, December 12th. Zacks Investment Research upgraded Tigenix from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, BidaskClub lowered Tigenix from a “sell” rating to a “strong sell” rating in a report on Saturday, December 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Tigenix currently has a consensus rating of “Hold” and an average price target of $34.50.

Shares of Tigenix (NASDAQ TIG) opened at $24.07 on Thursday. Tigenix has a fifty-two week low of $12.85 and a fifty-two week high of $26.20. The company has a quick ratio of 1.36, a current ratio of 1.37 and a debt-to-equity ratio of 0.10.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at

Tigenix Company Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Receive News & Ratings for Tigenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix and related companies with's FREE daily email newsletter.